<DOC>
	<DOCNO>NCT01924286</DOCNO>
	<brief_summary>Tuberculosis ( TB ) common opportunistic infection amongst HIV-infected patient start antiretroviral therapy ( ART ) develop country thus frequent form immune reconstitution inflammatory syndrome ( IRIS ) . Paradoxical TB-IRIS occurs 8- 43 % patient start ART TB treatment result morbidity , hospitalisation , consume health care resource TB-IRIS may fatal . We previously demonstrate clinical trial prednisone reduce morbidity use treatment paradoxical TB-IRIS . This trial double-blind placebo-controlled trial prophylactic prednisone ( 40mg/day 2 week follow 20mg/day 2 week , start day ART ) patient TB identify high risk paradoxical TB-IRIS ( start ART within 30 day initiate TB treatment CD4 &lt; 100/μL ) . The trial enroll 240 participant , randomise 1:1 ( prednisone : placebo ) . The primary endpoint development paradoxical TB-IRIS , define use international consensus case definition . Secondary endpoint include time IRIS event , severity IRIS , quality life assessment , mortality corticosteroid adverse event . The trial power determine reduction TB-IRIS event .</brief_summary>
	<brief_title>Preventing TB-IRIS High-risk Patients : Randomized Placebo-controlled Trial Prednisone</brief_title>
	<detailed_description>Objective : To determine whether addition prednisone first 4 week antiretroviral therapy ( ART ) reduce risk paradoxical TB-IRIS HIV-infected patient treat TB high risk develop TB-IRIS ( CD4 &lt; 100 cells/μl start ART within 30 day TB treatment ) . Design : A randomized double-blind placebo-controlled trial evaluate incidence paradoxical TB-IRIS first 12 week ART participant receive 4 week course prednisone versus participant receive 4 week course placebo . Primary efficacy endpoint : The development paradoxical TB-IRIS within 12 week start ART ( define use International Network Study HIV-associated IRIS ( INSHI ) consensus case definition ) . Secondary efficacy endpoint : 1 . Time IRIS event 2 . Severity IRIS event ( define following : need hospitalisation IRIS , C-reactive protein , neurological involvement ) 3 . Duration TB-IRIS event ( onset symptoms/signs resolution TB-IRIS symptoms/signs ) 4 . Mortality attribute TB TB-IRIS 5 . All-cause mortality 6 . Composite endpoint death , hospitalization , hepatotoxicity ( use protocol-specified definition Grade 3 4 increase ALT bilirubin ) . 7 . Other ( non-TB ) IRIS event 8 . Quality life assessment ( measure use PROQOL-HIV , EQ-5D-3L , HIV symptom index Karnofsky score ) 9 . Adverse event severe adverse event ascribe TB treatment , ART co-trimoxazole . This include pre-specified analysis drug-induced liver injury drug rash . This assessment include number treatment interruption drug adverse event . 10 . Discontinuation either ART TB treatment &gt; 5 day due adverse event 11 . Number hospitalization total day hospitalize Safety tolerability endpoint : 1 . Corticosteroid-associated adverse event , classify severity relation study drug . These include hypertension , hyperglycaemia , hypomania/mania , depression , acne , epigastric pain , upper gastro-intestinal bleeding , Cushingoid feature , new oedema avascular bone necrosis . 2 . Laboratory safety data : glucose , full blood count electrolytes 3 . Other infection ( AIDS-related , bacterial , fungal viral ) malignancy ( Kaposi 's sarcoma ) 4 . All grade 1 , 2 , 3 4 adverse event ( clinical laboratory use ACTG grade system ) Sample size : 240 participant enrol 13 month . Each participant follow 12 week . Population : HIV-infected , ART-naïve adult ( ≥ 18 year ) patient diagnose active tuberculosis CD4 &lt; 100 cells/μL start ART within 30 day start TB treatment . Other inclusion criterion include : diagnosis TB ( smear , culture , Xpert MTB/RIF test , histology strong clinical radiological evidence TB symptomatic response TB treatment ) , eligible consent start ART write informed consent trial . Exclusion criterion include : Kaposi 's sarcoma , pregnancy , TB meningitis tuberculoma TB diagnosis ( patient receive corticosteroid ) , know rifampicin-resistant TB , corticosteroids another indication within past 7 day , immunosuppressive medication within past 7 day uncontrolled diabetes mellitus . TB treatment ART : TB treatment prescribe monitored clinical staff local HIV-TB clinic . TB treatment give accord South African Department Health guideline . This involve rifampicin ( R ) , isoniazid ( H ) , ethambutol ( E ) pyrazinamide ( Z ) 2 month follow RH 4 month . ART prescribe clinical staff HIV-TB clinic accord South African Department Health guideline . Standard first line ART TB patient tenofovir , emtricitabine ( lamivudine ) efavirenz . Co-trimoxazole prophylaxis prescribe patient unless contra-indication exists . Intervention : Oral prednisone 40mg daily 14 dos start first day ART take , follow 20mg daily 14 dos ( identical placebo ) . A total 28 day study medication thus prescribe . Follow-up : Patients screen establish TB treatment , start ART . If patient eligible , write informed consent take . There six plan study visit relation start ART : week 0 ( day ART initiate ) , week 1 , week 2 , week 4 , week 8 week 12 . Patients see unscheduled visit clinical deterioration occur . If paradoxical TB-IRIS diagnose treat open label prednisone clinician discretion symptom moderate severe . If patient experience clinical complication ( eg . TB-IRIS ) follow-up prolong beyond week 12 order stabilize condition referral back general TB-HIV clinical service ongoing management . Data monitoring : The trial monitor independent Data Safety Monitoring Board ( DSMB ) comprise 3 independent researcher independent statistician . After initial meeting agree Charter , DSMB meet twice ( 80 160 participant complete follow-up ) review data quality data respect safety trial endpoint . If evidence harm relate study medication trial conduct DSMB may advise sponsor trial enrollment stop . Clinical trial site : Khayelitsha Site B HIV-TB clinic ( Ubuntu clinic ) Co-investigators : Lut Lynen ( Institute Tropical Medicine , Antwerp , Belgium ) Gary Maartens ( University Cape Town ) Robert J. Wilkinson ( Imperial College London University Cape Town ) Robert Colebunders ( Institute Tropical Medicine , Antwerp , Belgium )</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Immune Reconstitution Inflammatory Syndrome</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>1 . HIVinfected HIV infection confirm two different rapid test ( per South African national Department Health guideline ) HIV viral load test . 2 . CD4 count &lt; 100/μL One CD4 count take within 3 month prior enrolment le 100/μL qualify , even CD4 count great 100/μL 3 . ARTnaïve Patients report treat triple drug dual drug ART previously exclude . Single dose nevirapine short term AZT monotherapy PMTCT exclusion . 4 . Confirmed diagnosis TB ( smear , culture , Xpert MTB/RIF test compatible histology ) strong clinical radiological evidence TB symptomatic response TB treatment 5 . On TB treatment le 30 day prior study entry . 6 . Eligible ART patient consent start ART within 30 day start TB treatment . 7 . Written inform consent trial 1 . Kaposi 's sarcoma ( KS ) A thorough examination KS lesion perform suspicious lesion biopsied . Any history treatment KS also exclusion . 2 . Pregnant All female participant childbearing potential pregnancy test perform prior enrollment counsel use two reliable method contraception duration trial . 3 . &lt; 18 year old 4 . TB meningitis tuberculoma TB diagnosis 5 . Clinical syndrome pericardial TB TB diagnosis ( pericardial effusion note ultrasound scan alone exclusion criterion ) 6 . Rifampicinresistant TB diagnose Xpert MTB/RIF test drug susceptibility test perform culture isolate . 7 . On corticosteroid another indication immunosuppressive medication within past 7 day . 8 . Uncontrolled diabetes mellitus 9 . The follow abnormal laboratory value : Alanine aminotransferase &gt; 200 IU/l Absolute neutrophil count &lt; 500/mm3 10 . Not standard intensive phase TB treatment ( Rifampicin , isoniazid , pyrazinamide ethambutol ) 11 . Poor clinical response TB treatment prior ART judge clinical investigator . 12 . Hepatitis B surface antigen positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>Tuberculosis</keyword>
	<keyword>Immune reconstitution inflammatory syndrome</keyword>
	<keyword>Highly active antiretroviral therapy</keyword>
	<keyword>Glucocorticoids</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Preventive therapy</keyword>
</DOC>